home All News open_in_new Full Article

Nymox Announces Dismissal of Delaware Action Against Ascella

IRVINE, Calif., March 11, 2025 (GLOBE NEWSWIRE) — Nymox announces that it dismissed the Delaware matter pending against Ascella on March 7, 2025. A number of factors caused the company to reconsider its strategy to adequately protect its shareholders. Nymox CEO Paul Averback said, “The dismissal at this stage is a legal step after consultation […]



Nymox announced the dismissal of its Delaware action against Ascella on March 7, 2025. CEO Paul Averback stated the dismissal was a legal step after consulting with counsel. Nymox is seeking approval to market its drug NYMOZARFEX for BPH. The company also reported 10-year follow-up data from U.S. patients.

today 2 d. ago attach_file Other

attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Economics
attach_file Events
attach_file Other
attach_file Culture
attach_file Technology
attach_file Sport
attach_file Economics
attach_file Culture
attach_file Transport
attach_file Other
attach_file Economics
attach_file Other
attach_file Culture
attach_file Other
attach_file Other
attach_file Economics


ID: 2855290491
Add Watch Country

arrow_drop_down